Ocular FIP evidence grows as antiviral treatment guidance evolves

Ocular FIP treatment is getting sharper clinical definition as newer evidence fills in a gap that many veterinarians have faced in practice: how cats with eye involvement respond to antiviral therapy, and what dosing intensity may be needed. A 2025 observational case series of 20 cats with ocular feline infectious peritonitis found improvement in ocular disease with remdesivir, GS-441524, or both, addressing a presentation that had been less well described in prior antiviral reports. That builds on earlier FIP literature showing GS-441524 can be effective in cats with neurologic and ocular disease, and on broader 2024-2025 reviews, podcasts, and guidelines that increasingly treat ocular FIP as a higher-complexity form that may require higher dosing and close follow-up. Clinically, that matters because ocular signs may be the dominant presentation in some cats, especially in non-effusive disease, and can include anterior uveitis, keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, fibrinous exudate, retinal lesions, hemorrhage, vascular tortuosity, or detachment. In the U.S., this also lands against a changing access backdrop: compounded oral GS-441524 became available in June 2024, while FDA said it does not intend to enforce approval requirements for patient-specific compounded GS-441524 under certain conditions, even though compounded animal drugs remain unapproved. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, ocular FIP is no longer just a diagnostic red flag tied to a historically fatal disease; it's a presentation with growing evidence for treatment response, but not a one-size-fits-all protocol. Current guidance and published case material suggest cats with ocular or neurologic involvement may need higher-dose antiviral strategies than uncomplicated cases, and that route changes, prolonged therapy, relapse monitoring, and practical issues around oral tolerance or injectable pain can shape outcomes. Emerging discussion around treatment refinement also points to more objective stopping criteria, including trends in serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio, because early clinical improvement may not mean viral clearance. The legal shift to patient-specific compounded GS-441524 in the U.S. may also reduce reliance on unregulated products, which prior analysis found could vary substantially from labeled content, especially oral formulations. (abcdcatsvets.org)

What to watch: Expect more protocol refinement around ocular-specific dosing, relapse risk, comparative use of remdesivir versus GS-441524, and whether higher-dose induction plus biomarker-guided treatment duration can safely shorten therapy in selected cats. (pubmed.ncbi.nlm.nih.gov)